Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Janux Therapeutics Inc shares valued at $1,404,805 were purchased by Campbell David Alan on Dec 26 ’24. At $56.19 per share, Campbell David Alan acquired 25,000 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Campbell David Alan sold 15,000 shares, netting a total of over 1,005,000 in proceeds. Following the sale of shares at $67.00 each, the insider now holds 242,054 shares.
Before that, Campbell David Alan had sold 25,000 shares from its account. In a trade valued at $1,289,879, the President and CEO traded Janux Therapeutics Inc shares for $51.60 each. Upon closing the transaction, the insider’s holdings decreased to 25,000 shares, worth approximately $14.18 million.
As published in a research note from H.C. Wainwright on December 03, 2024, Janux Therapeutics Inc [JANX] has been retained to a Buy and the price target has been revised to $70. Analysts at BTIG Research resumed the stock at ‘”a Buy”‘ outlook in a report released in early December. As of November 22, 2024, Leerink Partners has initiated its “an Outperform” rating for JANX. Earlier on October 24, 2024, UBS initiated its rating. Their recommendation was “a Buy” for JANX stock.
Analyzing JANX Stock Performance
During the last five days, there has been a surge of approximately 0.07%. Over the course of the year, Janux Therapeutics Inc shares have jumped approximately 414.17%. Shares of the company reached a 52-week high of $71.71 on 12/05/24 and a 52-week low of $7.79 on 02/05/24. A 50-day SMA is recorded $54.28, while a 200-day SMA reached $47.17. Nevertheless, trading volume fell to 0.67 million shares from 0.33 million shares the previous day.
Support And Resistance Levels for Janux Therapeutics Inc (JANX)
According to the 24-hour chart, there is a support level at 54.44, which, if violated, would cause prices to drop to 53.70. In the upper region, resistance lies at 55.94. The next price resistance is at 56.70. RSI (Relative Strength Index) is 47.52 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.48, which suggests the price will decrease in the coming days. Percent R is at 93.44%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
